Blood conditions caused by complement activation represent a rare but very dangerous group of diseases that occur as a result of excessive activation of the complement pathway in the immune response system. The eculizumab medication represents an effective therapy that blocks this inappropriate immune reaction. Due to its use, the results obtained by patients who suffer from rare blood diseases have significantly improved.
What Is the Complement System and Why Is It Important?
Complement system refers to an important component of the body’s defense mechanism against infections and destruction of damaged cells. It comprises a group of proteins whose function involves a sequence of reactions to eliminate pathogenic agents. But sometimes this system gets over stimulated and acts against healthy cells including red blood cells, causing several diseases.
What Are Complement-Mediated Blood Disorders?
Complement-induced hematological disorders are conditions caused by excessive activity of the complement system that leads to destruction of red blood cells, formation of clots, and organ damage. Some common disorders are:
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
Such disorders are rare yet serious, and need specific treatment for proper management.
What Is Eculizumab?
The injection is an example of a monoclonal antibody that blocks the complement system selectively. It is administered through an intravenous drip in the body. Also the medicine marks a significant breakthrough in the treatment of complement-mediated disorders as it treats the actual cause instead of just the symptoms.
How Does The Medicine Work In The Body?
It acts through inhibition of C5, an important protein in the complement system. This leads to prevention of the formation of the membrane attack complex, which is involved in the destruction of the red blood cells. Through this mode of action, the medicine achieves the following:
● Reduction in the destruction of red blood cells.
● Prevention of clot formation.
● Organ protection.
In Which Conditions Is It Used?
Some of the indications where eculizumab may be administered include:
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Certain cases of generalized myasthenia gravis (gMG)
- Neuromyelitis optica spectrum disorder (NMOSD)
This therapy is dependent upon the medical assessment of the condition.
What Are the Benefits of Therapy?
There are many advantages to using this treatment, including:
- Specific effect on the complement system
- Decreased hemolysis (damage to red blood cells)
- Decreased thrombosis (formation of clots)
- Enhanced quality of life
- Decreased need for blood transfusion
It has revolutionized the outcome of treatment in patients suffering from rare diseases of blood.
What Are the Possible Side Effects of The Medicine?
Although the treatment is quite effective, there are some side effects that might go along with it, which must be monitored carefully.
- Headache
- Nausea
- Fever
- Tiredness
- Upper respiratory infection
The risk of meningococcal infection is high and hence patients need to be vaccinated prior to the use of the drug.
Which Brand of The Medication Is Available?
The name of eculizumab brand is:
Please note that this medicine needs to be taken strictly according to medical advice.
Why Is Monitoring Important During Treatment?
Regular monitoring is key when being treated with this targeted therapy. These can be:
- Regular blood tests for cell count
- Kidney function tests
- Tests for infections
- Assessment of symptoms
These safety tips help to adjust the treatment and avoid any potential problems.
Does This Injection Interact with Other medications?
The medicine can also have drug interactions with some medications that affect the immune system. Some other factors to be considered are:
- Immunosuppressants
- Vaccines (live vaccines in particular)
- Biologics
The patient must inform their healthcare provider regarding any other medications they are currently taking or if they cause any side effects.
Conclusion
The medicine is a significant step forward in treating disorders in the blood that occur due to complement activation. As it acts on the root cause of the illness, it proves to be a more efficient method compared to other types of therapy available. Despite its need for constant monitoring, it has greatly enhanced the outcome of people suffering from hematologic disorders.
FAQs
1. Can eculizumab cure disease permanently?
It cannot be used for a complete cure of the disease, but it can be quite effective for controlling the symptoms.
2. How long the medicine should be taken?
The duration and dose of the treatment on the type of disease and patient reaction to the therapy. However, always discuss with the doctor, in case of any doubt.
References
- Luo, S., Hu, D., Wang, M., Zipfel, P. F., & Hu, Y. (2020). Complement in hemolysis-and thrombosis-related diseases. Frontiers in immunology, 11, 1212. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01212/full
- Baines, A. C., & Brodsky, R. A. (2017). Complementopathies. Blood reviews, 31(4), 213-223. https://pubmed.ncbi.nlm.nih.gov/28215731/
- Wijnsma, K. L., Ter Heine, R., Moes, D. J. A., Langemeijer, S., Schols, S. E., Volokhina, E. B., … & Brüggemann, R. J. (2019). Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clinical pharmacokinetics, 58(7), 859-874. https://link.springer.com/article/10.1007/s40262-019-00742-8
- Dmytrijuk, A., Robie-Suh, K., Cohen, M. H., Rieves, D., Weiss, K., & Pazdur, R. (2008). FDA report: eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. The oncologist, 13(9), 993-1000.https://pubmed.ncbi.nlm.nih.gov/18784156/
- Davis, J. (2008). Eculizumab. American Journal of Health-System Pharmacy, 65(17), 1609-1615. https://pubmed.ncbi.nlm.nih.gov/18714106/
